Immunic Inc. Common Stock (IMUX)
Stock · NASDAQ · Health Care
$6.93as of 10/16/2026
Price chart
Active signals
IMUX Signal Track Record
How signals performed across all stocks →What IMUX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 30 | -2.1% | 43% | September 17, 2026 |
| Bollinger Band Breakout | 26 | -11.4% | 31% | August 12, 2026 |
| Bollinger Band Breakdown | 21 | +6.5% | 57% | September 3, 2026 |
| 200-Day Moving Average TouchActive now | 11 | -11.9% | 18% | September 14, 2026 |
| Any 20-session window (baseline) | -3.1% | 44% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About IMUX
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 100
- Website
- imux.com
Fundamentals
- 1-day range
- $6.59$7.14
- Market cap
- $198.06M
- P/E (trailing)
- —
- P/E (forward)
- -2.93
- EPS (trailing)
- $-4.20
- Dividend yield
- —
- Beta
- 1.47
- Avg. volume
- 301.6K
- Dividend pay date
- April 15, 2019
Forecasts
11 analyst ratings
Immunic Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- IMUXImmunic Inc. Common Stock$6.97▼ 1.83%Market cap $198.06MP/E —$5.06$17.43
- NBPNovaBridge Biosciences American Depositary Shares$1.26▼ 2.33%Market cap $196.15MP/E —$1.26$6.79
- NERVMinerva Neurosciences Inc Common Stock$2.35▼ 2.89%Market cap $206.85MP/E —$2.31$12.46
- GLSIGreenwich LifeSciences Inc. Common Stock$14.55▼ 5.03%Market cap $209.02MP/E —$7.78$34.1
- MSLESatellos Bioscience Inc. Common Stock$6.46▼ 5.56%Market cap $209.77MP/E —$7.56$18.98
- TNXPTonix Pharmaceuticals Holding Corp. Common Stock$6.04▼ 5.92%Market cap $185.71MP/E —$6.01$20.69
- KROSKeros Therapeutics Inc. Common Stock$10.66▼ 3.96%Market cap $211.16MP/E —$9.69$22.55
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| IMUX Immunic Inc. Common Stock | $198.06M | — | $6.97 | ▼ 1.83% | $5.06$17.43 |
| NBP NovaBridge Biosciences American Depositary Shares | $196.15M | — | $1.26 | ▼ 2.33% | $1.26$6.79 |
| NERV Minerva Neurosciences Inc Common Stock | $206.85M | — | $2.35 | ▼ 2.89% | $2.31$12.46 |
| GLSI Greenwich LifeSciences Inc. Common Stock | $209.02M | — | $14.55 | ▼ 5.03% | $7.78$34.1 |
| MSLE Satellos Bioscience Inc. Common Stock | $209.77M | — | $6.46 | ▼ 5.56% | $7.56$18.98 |
| TNXP Tonix Pharmaceuticals Holding Corp. Common Stock | $185.71M | — | $6.04 | ▼ 5.92% | $6.01$20.69 |
| KROS Keros Therapeutics Inc. Common Stock | $211.16M | — | $10.66 | ▼ 3.96% | $9.69$22.55 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Immunic to present four vidofludimus calcium abstracts at MSToronto2026Yahoo · 10/7/2026
- Immunic Announces Acceptance Of Four Abstracts At MSToronto2026 – the 10th Joint ACTRIMS-ECTRIMS Meetingbenzinga · 10/7/2026
- Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS MeetingYahoo · 10/7/2026
- Immunic Announces Acceptance Of Four Abstracts At MSToronto2026 – the 10th Joint ACTRIMS-ECTRIMS MeetingBenzinga · 10/7/2026
- Immunic, Inc. (IMUX) Discusses R&D Advances and Future Directions in Relapsing Multiple Sclerosis TranscriptSeekingAlpha · 9/11/2026
Insider Activity
Insider Actions →- Nagel Robert Thorvald · September 16, 2026 · Grant25.4K
- BVF PARTNERS L P/IL · September 16, 2026 · Grant25.4K
- Elena Ridloff · August 6, 2026 · Grant50.7K
- Skerjanec Simona · July 5, 2026 · Grant25.4K
- Rudick Richard Alan · July 5, 2026 · Grant25.4K
- Neermann Joerg · July 5, 2026 · Grant25.4K
- Jon Congleton · July 5, 2026 · Grant25.4K
- PHILLIPS BARCLAY A · July 5, 2026 · Grant25.4K
- Lundgren Erik · May 22, 2026 · Grant1.00M
- Panzara Michael A. · April 24, 2026 · Grant300.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 953.0K
- Total value held
- $1.06M
- Institutional holders
- 3
- Unknown953.0K
- Unknown3
- Unknown2
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Immunic Presents Four Abstracts at MSToronto2026
Immunic announced that four of its research abstracts were accepted for presentation at the 10th Joint ACTRIMS-ECTRIMS Meeting, known as MSToronto2026. This event highlights the company's ongoing scientific activity in its field. The stock is currently trading near its 52-week low, with an RSI of 22.5 indicating oversold conditions.
Immunic Presents Four Abstracts at MSToronto2026. Immunic announced that four of its research abstracts were accepted for presentation at the 10th Joint ACTRIMS-ECTRIMS Meeting, known as MSToronto2026. This event highlights the company's ongoing scientific activity in its field. The stock is currently trading near its 52-week low, with an RSI of 22.5 indicating oversold conditions.